FindTrial
Sign In

Comparison of efficacy between adalimumab 80mg every other week vs 40mg every week in Crohn's disease(WAVE-K study)

Comparison of efficacy between adalimumab 80mg every other week vs 40mg every week in Crohn's disease(WAVE-K study) - Comparison of efficacy between adalimumab 80mg every other week vs 40mg every week in Crohn's disease(WAVE-K study)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000023871
Enrollment
100
Registered
2016-09-01
Start date
2016-08-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

Administration of Adalimumab 80 mg every 2 weeks. Administration of Adalimumab 40 mg every week.

Sponsors

Fukuoka University Chikushi Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Crohn's disease patients who lost response (HBI>4) under adalimumab 40mg EOW treatment.

Exclusion criteria

Exclusion criteria: Patients who have symptomatic stenosis Patients who have fistula Patients who are considered inadequate by investigator

Design outcomes

Primary

MeasureTime frame
Harvey Bradshaw Index remission (<4) rate at week 52—

Secondary

MeasureTime frame
Serum ADA/AAA concentration at baseline and week 52 Safety profile through 52 weeks—

Countries

Japan

Contacts

Public ContactTeruyuki Takeda

Fukuoka University Chikushi Hospital Inflammatory Bowel Disease Center

take5times@hotmail.co.jp092-921-1011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026